Protara Therapeutics reported Q3 2026 results, highlighting progress in clinical trials for TARA-002 in bladder cancer and lymphatic malformations, and IV Choline Chloride for patients on parenteral support. They expect to complete enrollment in key trials by early 2027 and initiate regulatory submissions later that year. The company acquired manufacturing assets to support commercial launch and holds $143 million in cash, sufficient to fund operations into 2028. These developments position Protara for potential regulatory milestones and product launches in 2027 and beyond.
Protara Therapeutics' Q3 2026 financial results and business update provide context for readers following health sector stocks. As of Nov 06, 2026 19:41 WIB, out of 150 priced health-sector US stocks tradable on Pluang, 52 rose and 90 fell. Notable movers include BKD at USD 9.40 with a 1-day change of -13.04%, TMDX at USD 77.25 with a 1-day change of +11.99% and 100% buy order activity, and GMED at USD 73.91 with a 1-day change of -9.34%.
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
Guggenheim analyst Howard Ma raised JFrog's price target to $125, signaling a 67.5% potential upside from its current price of $74.62. JFrog reported strong Q3 2026 results with revenue up 31% year-over-year to $179.2 million, driven by a 60% surge i...
The Indonesia data center market is projected to grow from USD 2.08 billion in 2027 to USD 4.05 billion by 2032, at a CAGR of 14.28%. Growth is fueled by expanding hyperscaler cloud infrastructure, rising digital workloads, increasing demand for colo...
Investing $300,000 equally in three high-dividend stocks—Realty Income, Verizon, and Ares Capital—can yield over $21,500 in passive income annually. Realty Income offers a 5.53% yield with monthly dividends from net-lease properties, Verizon provides...
Paycom Software, Inc. reported strong Q3 2026 results, with revenue up 10% year-over-year and non-GAAP EPS increasing by 37%. The company's adjusted EBITDA margin expanded to 49.3%, and recurring revenue reached 95.5% of total, driven by successful u...
